Chris Dockendorff, Ph.D.
CSO & CEO
Dr. Dockendorff is an organic and medicinal chemist with a passion for the design, synthesis, and study of novel molecules with the potential to improve human health. Prior to leading the team at Function Therapeutics, he was a faculty member at Marquette University, where he led a team of scientists developing new probe molecules and drug candidates via the modification and redesign of natural and unnatural compounds, and also novel catalysts. He is the co-author of more than 60 scientific papers and patent applications, and is the inventor of parmodulin compounds and modified opioids presently under investigation for several indications. Previously, he was a scientist at the Broad Institute, University of Texas at Austin, and NPS Pharmaceuticals. Chris obtained his B.Sc. from the University of Waterloo, and Ph.D. from the University of Toronto.
Paul Ornstein, Ph.D.
VP of Preclinical Development
Dr. Ornstein has close to 40 years of drug discovery experience as a medicinal chemist at Eli Lilly, followed by faculty positions at Roosevelt University and the Medical College of Wisconsin. His focus has been the development of valuable ligands for excitatory amino acid receptors, GPCRs, and ion channels. He is presently the principal of Apollo Drug Discovery Consulting, and has published more than 175 issued patents and publications. Paul obtained his B.S. from UCLA, Ph.D. from the University of Wisconsin, and was a postdoctoral researcher with Prof. David Evans.
Scientific Advisory Board
William Greenlee, Ph.D.
Dr. Greenlee is an independent medicinal chemistry consultant and former senior director and vice president of chemistry at Merck Research Labs and Schering-Plough Research Institute, where he specialized in cardiovascular and CNS-related indications. He provided leadership to research groups that advanced 20 drug candidates into preclinical development and 11 into clinical studies, including the marketed drugs Vasotec™, Prinivil™, and Zontivity™. He is co-author of over 240 publications and co-inventor of over 80 U.S. patents. He was elected as a fellow of the American Chemical Society, the American Association for the Advancement of Science, and in 2004 was given the Alfred Burger Award and inducted into the ACS Medicinal Chemistry Hall of Fame. Dr. Greenlee holds a B.S. from the Ohio State University, and a Ph.D. from Harvard University, where he worked with Nobel laureate R. B. Woodward.
Robert Flaumenhaft, M.D., Ph.D.
Dr. Flaumenhaft is Professor of Medicine at Harvard Medical School and presently Chief of the Division of Hemostasis and Thrombosis at Beth Israel Deaconess Medical Center. His lab discovered that certain antithrombotic small molecules (called parmodulins) act as allosteric ligands of protease-activated receptor 1 (PAR1), and these molecules also have valuable anti-inflammatory properties. His work in platelet biology and thrombotic mechanisms has earned him a Career Award from the Burroughs Wellcome Fund, a Junior Faculty Award from the American Society of Hematology, an Established Investigator Award from the American Heart Association, and an R35 Outstanding Investigator grant from the National Heart, Lung, and Blood Institute. He was also elected to the American Society for Clinical Investigation, and the Association of American Physicians. He received his B.S. from Haverford College and M.D. and Ph.D. degrees from New York University.
Hartmut Weiler, Ph.D.
Dr. Weiler is a Senior Investigator at the Versiti Blood Research Institute. He is a world expert in coagulation, inflammation biology, sepsis, and hematopoesis, and his lab performed key studies helping to determine the mode of action of activated protein C (aPC) as an anti-inflammatory and anti-sepsis agent. He recently received the International Society on Thrombosis and Haemostasis Esteemed Career Award. Dr. Weiler received B.S., M.S., and Ph.D. degrees from Technische Hochschule Darmstadt.
Berend Isermann, M.D.
Dr. Isermann is Professor of Laboratory Medicine and Clinical Chemistry at Leipzig University. He is a world expert in the role of endothelial dysfunction and coagulation protease-dependent signaling in the context of chronic vascular disease and reproductive biology. His lab has determined the relevance of protease-activated receptors to kidney disease and ischemia-reperfusion disease, and in particular determined that parmodulins mimic the anti-inflammatory actions of aPC in mouse models of myocardial infarction and diabetic nephropathy. In 2018 he received the German Bioregion Innovation Prize, and from 2017-19 was President of the German Society of Clinical Pathology and Clinical Chemistry. He holds an M.D. from University Würzburg.
Joseph Lorenzo, M.D.
Dr. Lorenzo is Professor of Medicine and Orthopaedics and Director of Bone Biology Research at the University of Connecticut Health Center, where he has performed basic and clinical endocrinology since 1979. He has extensive experience in the treatment of osteoporosis and other metabolic bone diseases, including the characterization of osteoclast formation and function. Recently, his lab determined that PAR1-targeting parmodulins inhibit osteoclast formation and bone resorption in vitro and in vivo. Dr. Lorenzo received his B.S. from Rensselaer Polytechnic Institute and M.D. from the State University of New York, Downstate Medical Center.